Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.46% | -44.68% | -42.15% | -58.31% | -54.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.67% | -57.67% | -42.36% | -54.49% | -54.39% |
| Operating Income | 45.67% | 57.67% | 42.36% | 54.49% | 54.39% |
| Income Before Tax | 35.90% | 105.57% | 93.25% | 92.52% | 59.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.90% | 105.57% | 93.25% | 92.52% | 59.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.90% | 105.57% | 93.25% | 92.52% | 59.65% |
| EBIT | 45.67% | 57.67% | 42.36% | 54.49% | 54.39% |
| EBITDA | 45.88% | 57.81% | 42.30% | 54.56% | 54.45% |
| EPS Basic | 38.83% | 107.88% | 94.72% | 92.71% | 85.76% |
| Normalized Basic EPS | -3.57% | 33.33% | 37.39% | 55.69% | 80.81% |
| EPS Diluted | 42.63% | 105.57% | 92.95% | 91.51% | 84.81% |
| Normalized Diluted EPS | -3.57% | 33.33% | 37.39% | 55.69% | 80.81% |
| Average Basic Shares Outstanding | 22.86% | 30.52% | 37.18% | 32.34% | 129.62% |
| Average Diluted Shares Outstanding | 22.86% | 30.52% | 37.18% | 32.34% | 129.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |